Lung Cancer

Latest News

Adjuvant Osimertinib Prolongs OS in Early-Stage EGFR-Mutated NSCLC

March 12th 2023

Patients with stage IB, II, or IIIA, EGFR-mutated non–small cell lung cancer derived benefit with adjuvant osimertinib.

lung cancer
Pembrolizumab Misses Mark in mCRPC, EGFR-Mutant NSCLC Trials

March 5th 2023

FDA Approval
Adjuvant Pembrolizumab Gets FDA Approval in NSCLC

January 26th 2023

Children Exposed to Maternal Cancer Show Normal Cognitive and Behavioral Outcomes

January 24th 2023

lung cancer
Frontline Durvalumab Does Not Elicit Significant OS Improvement in Advanced, PD-L1-High NSCLC

December 29th 2022

Video Series
Video Interviews
Oncology Nursing News
Are Hearing Tests Necessary For Adult Cancer Survivors?
Key Advances in Cancer Survivorship Toxicity Management

More News

© 2023 MJH Life Sciences

All rights reserved.